OrganOmics

OrganOmics is a biotechnology startup based in the United States, founded in 2021 with the slogan "Human Tissues for Human Therapeutics." The company is revolutionizing preclinical drug discovery with their cutting-edge live human brain tissue models derived from stem cells, as well as patient-derived cancer tissue to induce realistic cancer pathology in collaboration with neurosurgeons. Their patented microfluidic platform automates assays, detailing drug responses of thousands of tissues and generating vast, high-content data. This data is processed through artificial intelligence to predict the clinical outcomes of candidate drugs. The last investment in OrganOmics was a Non-Equity Assistance investment at 15 February 2021, and it was provided by CITRIS Foundry. This innovative approach to preclinical drug discovery in the field of biotechnology and healthcare has attracted attention from investors and stakeholders. OrganOmics demonstrates impressive potential in shaping the future of drug discovery by leveraging advanced technology and breakthrough scientific models. With its focus on harnessing the power of engineered tissue and AI, the company stands as a promising player in the biotechnology and healthcare industries. As the demand for advanced preclinical drug discovery solutions grows, OrganOmics holds significant promise for generating impactful outcomes for the biotechnology and healthcare sectors.